Antitumor Activity of Tiazofurin in Human Colon Carcinoma HT-29

References

• Robins R K, Srivastava P C, Narayanan V L. 2-|3-D-Ribo-furanosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J Med Chem 1982; 25: 107–108
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, Shoemaker D D, Jayaram H N. Tiazofurin: a new antitumor agent. Invest New Drugs 1984; 2: 79–84
   PubMed Web of Science ®Google Scholar
• Ahluwalia G S, Jayaram H N, Plowman J P. Studies on the mechanism of action of 2-/8-D-ribofuranosylthiazole-4-carbox-amide. V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol 1984; 33: 1195–1203
   PubMed Web of Science ®Google Scholar
• Jayaram H N, Smith A L, Glazer R I. Studies on the mechanism of action of 2-j3-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 1982; 31: 3839–3845
   PubMed Web of Science ®Google Scholar
• Earle M F, Glazer R I. Activity and metabolism of 2-/3-D-ribo-furanosyIthiazole-4-carboxamide in human lymphoid tumor cells in culture. Cancer Res 1983; 43: 133–137
   PubMed Web of Science ®Google Scholar
• Carney D N, Ahluwalia G S, Jayaram H N. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. J Clin Invest 1985; 75: 175–182
   PubMed Web of Science ®Google Scholar
• Tricot G J, Jayaram H N, Nichols C R. Hematological and biochemical action of tiazofurin in a case of refractory acute myeloid leukemia. Cancer Res 1987; 47: 4988–4991
   PubMed Web of Science ®Google Scholar
• Tricot G J, Jayaram H N, Lapis E. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res 1989; 49: 3696–3701
   PubMed Web of Science ®Google Scholar
• Weber G, Yamaji Y, Olah E. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin. Adv Enzyme Regul 1989; 28: 335–356
   PubMedGoogle Scholar
• Cooney D A, Jayaram H N, Gebeyehu G. The conversion of 2-)8-D-ribofuranosylfhiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase inhibitory properties. Biochem Pharmacol 1982; 31: 2133–2136
   PubMed Web of Science ®Google Scholar
• Cooney D A, Jayaram H N, Glazer R I. Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase inhibitory activity. Adv Enzyme Regul 1983; 21: 271–303
   PubMedGoogle Scholar
• Jayaram H N, Dion R L, Glazer R I. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-/3-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol 1982; 31: 2371–2380
   PubMed Web of Science ®Google Scholar
• Jayaram H N, Cooney D A, Glazer R I. Mechanism of resistance to the oncolytic C-nucleoside, 2-/3-D-ribofuranosylthia-zole-4-carboxamide (NSC 286193). Biochem Pharmacol 1982; 31: 2557–2560
   PubMed Web of Science ®Google Scholar
• Lui M S, Faderan M A, Liepnieks J J. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide). J Biol Chem 1984; 259: 5078–5082
   PubMed Web of Science ®Google Scholar
• Kuttan R, Robins R K, Saunders P P. Inhibition of inosinate dehydrogenase by metabolite of 2-β-D-ribofuranosylthiazole-4-car-boxamide. Biochem Biophys Res Commun 1982; 107: 862–868
   PubMed Web of Science ®Google Scholar
• Jayaram H N. Biochemical mechanisms of resistance to tiazofurin. Adv Enzyme Regul 1986; 24: 67–89
   Google Scholar
• Jayaram H N, Pillwein K, Lui M S. Mechanism of resistance to tiazofurin in hepatoma 3924A. Biochem Pharmacol 1986; 35: 587–593
   PubMed Web of Science ®Google Scholar
• Jayaram H N, Pillwein K, Nichols C R. Selective sensitivity to tiazofurin of human leukemic cells. Biochem Pharmacol 1986; 35: 2029–2032
   PubMed Web of Science ®Google Scholar
• Zhen W, Jayaram H N, Weber G. Determination of thiazole-4-carboxamide adenine dinucleotide (TAD) levels in mononuclear cells of leukemic patients treated with tiazofurin. Biochem Pharmacol 1991; 41: 281–286
   PubMed Web of Science ®Google Scholar
• Trump D L, Tutsch K D, Koeller J M. Phase I clinical study with pharmacokinetic analysis of 2-;8-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res 1985; 45: 2853–2858
   PubMed Web of Science ®Google Scholar
• Batist G, Klecker R W, Jayaram H N. Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion. Invest New Drugs 1985; 3: 349–355
   PubMed Web of Science ®Google Scholar
• Maroun J A, Eisenhauer E, Cripps C. Phase II study of tiazofurin in colorectal cancer: a National Cancer Institute of Canada study. Cancer Treat Rep 1987; 71: 1297–1298
   PubMedGoogle Scholar
• Natsumeda Y, Lui M S, Emrani J. Purine enzymology of human colon carcinomas. Cancer Res 1985; 45: 2556–2559
   PubMed Web of Science ®Google Scholar
• Weber G, Stubbs M, Morris H P. Metabolism of hepatomas of different growth rates in situ and during ischemia. Cancer Res 1971; 31: 2177–2183
   PubMed Web of Science ®Google Scholar
• Pillwein K, Jayaram H N, Weber G. Effect of ischemia on nucleosides and bases in rat liver and hepatoma 3924A. Cancer Res 1987; 47: 3092–3096
   PubMed Web of Science ®Google Scholar
• Khym J X. An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchanges. Clin Chem 1975; 21: 1245–1252
   PubMed Web of Science ®Google Scholar
• Weber G. Enzymology of cancer cells. N Engl J Med 1977; 296: 486–493; 541–551
   PubMed Web of Science ®Google Scholar
• Weber G. Biochemical strategy of cancer cells and the design of chemotherapy. G. H. A. Clowes Memorial Lecture. Cancer Res 1983; 43: 3466–3492
   PubMed Web of Science ®Google Scholar